Drugs that contain Gilteritinib Fumarate
1. List of Xospata drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jan, 2031
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(7 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
| New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
NCE-1 date: November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic